Zarif K. Lopez-Jabbar

St John's Institute Of Dermatology, King's College London And Guy's And St Thomas' NHS Foundation Trust
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis.

Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis.

Journal: Dermatology and therapy

Published: April 22, 2026

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 10, 2025

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies.

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 01, 2025

Content Validity and Psychometric Validation of an Adapted Version of the Subject Sleep Diary in Prurigo Nodularis.

Content Validity and Psychometric Validation of an Adapted Version of the Subject Sleep Diary in Prurigo Nodularis.

Journal: Dermatology and therapy

Published: March 06, 2025

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.

Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.

Journal: JAMA dermatology

Published: November 27, 2024

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.

Journal: The New England journal of medicine

Published: October 27, 2023

Patient Perspectives on Living With Severe Prurigo Nodularis.

Patient Perspectives on Living With Severe Prurigo Nodularis.

Journal: JAMA dermatology

Published: September 20, 2023

Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.

Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.

Journal: Dermatology and therapy

Published: August 01, 2023

The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.

The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.

Journal: Dermatology and therapy

Published: April 17, 2023

Incident Comorbidity, Resource Use, and All-Cause Mortality Associated with Prurigo Nodularis: A United Kingdom Retrospective Database Analysis.

Incident Comorbidity, Resource Use, and All-Cause Mortality Associated with Prurigo Nodularis: A United Kingdom Retrospective Database Analysis.

Journal: JID innovations : skin science from molecules to population health

Published: February 16, 2023

Epidemiology of prurigo nodularis in England: a retrospective database analysis.

Epidemiology of prurigo nodularis in England: a retrospective database analysis.

Journal: The British journal of dermatology

Published: November 15, 2021

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents.

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents.

Journal: Dermatology and therapy

Published: November 01, 2021

Showing 1-12 of 31

Last Updated: 09/26/2026